Dr. Daniel Wynn MD
Director, Clinical Research, CONSULTANTS IN NEUROLOGY LTD
Member of the Healthcare Council
Council Member Biography
Daniel Wynn, MD, FACN, FAASM, is the Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 130 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic pain and migraine, epilepsy, Parkinson's disease, sleep disorders, attention deficit hyperactivity disorder (ADHD), and others. Dr. Wynn serves on the Clinical Advisory Committee of National Multiple Sclerosis Society and is the Director of Consultants in Neurology Multiple Sclerosis Center. He is a member of numerous professional organizations including Alpha Omega Alpha Honor Medical Society, American Academy of Neurology, and American Medical Association. Dr. Wynn is widely published in The New England Journal of Medicine, Neurology, Annals of Neurology, Lancet, and Journal of the AMA, Pediatrics, Mayo Clinic Proceedings, and presents frequently at meetings in the US and overseas. (This is me - Update Profile)
Employment History
- 1988 - Unspecified
- Director, Clinical Research, CONSULTANTS IN NEUROLOGY LTD
- 1988 - Unspecified
- Director, Multiple Sclerosis Center, CONSULTANTS IN NEUROLOGY LTD
GLG NewsSM Analyses by Daniel Wynn
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Central Neuropathic Pain: Cymbalta--- Another Failed Trial
December 29, 2010
Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: A randomized, double-blind, placebo-controlled trial. | www.ncbi.nlm.nih.gov
Treatment of neuropathic pain remains an enigmatic dilemma for most physicians. Presently there are no drugs FDA approved for central neuropathic pain. The use of drugs utilized for diabetic peripheral neuropathy and fibromyalgia, most notably Cymbalta (Eli Lilly), Lyrica (Pfizer) and Savella (Forest), as well as generics such as gabapentin, tricyclic antidepressants and older anticonvulsants remain the mainstay of therapy.
-
Fampridine-PR -- The First Drug Proven to Help Multiple Sclerosis Patients Walk!
January 19, 2010
Biogen Idec Submits Application in Europe for the Approval of Fampridine-PR Tablets to Improve Walking Ability in People with Multiple Sclerosis | www.pipelinereview.com
Being confined to a wheelchair is the most common fear of patients living with multiple sclerosis (MS) from the time of diagnosis. Up until now, there have been no therapies demonstrated to improve walking in multiple sclerosis.Fampridine-PR is the first drug application for a product which has clearly shown to improve walking speed in a significant portion of MS patients, and may become the first drug specifically approved for this indication.
-
Acorda's Fampridine: The First FDA Approval to Help MS Patient's Walk
December 14, 2009
FDA Questions Efficacy of Acorda's MS Drug (Fampridine SR) | www.thestreet.com
Fampridine SR improves multiple sclerosis patient's ability to walk. In demonstrating this, Acorda has successfully demonstrated that a new class of therapeutics, potassium channel blockers, can be effectively employed to address MS symptoms effectively and safely.
-
Fampridine-SR -- anxiously awaited new MS therapeutic
June 2, 2009
Acorda’s Fampridine-SR Gets Priority Review | phoenix.corporate-ir.net
A major unmet need in the treatment of Multiple Sclerosis is a medication to increase walking ability. Since disease modifying therapies have only been available for 16 years, MS starts at a mean age of 29, and the disease has only a minimal effect at shortening lifespan, the majority of MS patients presently have progressive forms of MS. Ten percent have primary progressive disease, progressive from the onset, and others, start with relapsing remitting MS, and progress after approximately 15 years to progressive illness. In the early years of progressive MS, patients loose the ability to walk, hence the prior motto of the National MS Society, "MS, the great crippler of young adults." FAMPRIDINE SR IS THE FIRST MEDICATION FOUND TO IMPROVE MS PATIENTS ABILITY TO WALK. Standard disease modifying agents, the interferons (Avonex, Betaseron, Rebif), Copaxone and Tysabri, decrease relapse rate and may slow progression, however do not improve one's ability to walk.
-
NUVIGIL for Jet Lag -- An Important Broad New Indication for Cephalon
June 2, 2009
Cephalon to apply for FDA approval for Nuvigil for jet lag | www.reuters.com
NUVIGIL, Cephalon's single isomer longer effective half-life follow-up product to Provigil is coming to market only after careful strategic planning. While extremely successful, Provigil, a unique wake promoting agent, suffered in many ways. When introduced, it had only FDA approval for narcolepsy, a relatively uncommon, yet severe sleep disorder. Sales increased markedly when Provigil became approved for other common conditions associated with excessive daytime sleepiness (EDS), treated obstructive sleep apnea with residual EDS and sleep wake shift disturbance (SWSD). If approved for Jet Lag, there is the promise that Nuvigil will become available for an increasing enlarging marketplace.
GLG Study Groups with Daniel Wynn(?)
| Study Group Name | No. Members |
|---|---|
| Neurologists | 1902 |
| Neurologists (US) | 1104 |
| Physicians who Prescribe Opioids | 680 |
| Physicians who Treat Diabetes (US) | 637 |
| Physicians who Treat Insomnia (US) | 619 |
GLG Live Meetings with Daniel Wynn(?)
GLG Webcasts & Teleconferences
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.